【摘要】 目的:探讨GPIa C807T和G873A基因多态性对血小板聚集抑制率的影响，为临床个体化抗血小板聚集治疗提供实验数据支持。方法:收集正在使用阿司匹林抗血小板聚集治疗的住院患者80例，采用血栓弹力图仪检测血小板聚集抑制率，根据聚集抑制率检测结果分为阿司匹林抵抗(aspirin resistance, AR)组(共10例)和阿司匹林敏感(aspirin sensitivity, AS)组(共70例),分析GPIa C807T、G873A基因型及其等位基因在两组分布状况以及两者患者临床资料与实验检测指标关系。结果:AR组807T、873G等位基因高于AS组(χ~2=4.039、4.354,P=0.044、0.037);AR组高血压病史患病率、卒中史高于AS组(χ~2=4.612、4.737,P=0.032、0.030);AR组血浆D-二聚体(D-D)、血清甘油三酯(TG)高于AS组(t=2.499、2.276,P=0.016、0.033),而AR组血小板聚集抑制率、血清葡萄糖低于AS组(t=15.352、3.076,P<0.001、0.005)。结论:GPIa C807T和G873A基因多态性与AR存在相关性，建议联合检测两基因位点的多态性并结合血小板聚集抑制率，共同指导临床个体化抗血小板聚集治疗。更多还原

【Abstract】 Objective:To explore the effect of GPIa C807T and G873A gene polymorphisms on platelet aggregation inhibition rate, aiming to provide experimental data for clinical individualized antiplatelet aggregation therapy. Methods:A total of 80 inpatients receiving antiplatelet treatment with aspirin were collected and divided into two groups according to the inhibition rate of platelet aggregation detected by thromboelastography.10 patients were divided into the aspirin resistance(AR) group and 70 patients into the aspirin sensitive(AS) group. The genotypes of GPIa C807T, G873A and their allele distribution in the two groups were analyzed, and the relationship between clinical data and experimental indicators of the two groups were also analyzed. Results:The 807T and 873G alleles in the AR group were higher than those in the AS group(χ~2=4.039, 4.354, P=0.044, 0.037). The prevalence of hypertension and stroke history in the AR group was higher than that in the AS group(χ~2=4.612, 4.737, P=0.032, 0.030). Plasma D-dimer(D-D) and serum triglyceride(TG) in the AR group were higher than those in the AS group(t=2.499, 2.276, P=0.016, 0.033), while platelet aggregation inhibition rate(IPA) and serum glucose(GLU) in the AR group were lower than those in the AS group(t=15.352, 3.076, P<0.001, 0.005). Conclusion:GPIa C807T and G873A gene polymorphism were correlated with aspirin resistance. Joint detection of the two gene loci polymorphisms and platelet aggregation inhibition rate was recommended to jointly guide the clinical individualized antiplatelet aggregation therapy.更多还原